Active Biotech AB Interim report January - June 2015
August 07 2015 - 2:30AM
· Operations focused on the laquinimod
projects and organization adjusted accordingly
Laquinimod
· The pivotal CONCERTO clinical Phase III study in relapsing
remitting MS (RRMS) is fully enrolled and results are expected in
2017
· The first patient was enrolled for the ARPEGGIO Phase II
study, which will evaluate laquinimod's potential for treatment of
primary progressive multiple sclerosis (PPMS)
· The Phase II study LEGATO-HD into Huntington's disease is
proceeding according to plan
· Laquinimod presented by Teva at the AAN Annual Meeting on
April 18-25, 2015
Tasquinimod
· Results from the Phase III study 10TASQ10 showed that
treatment with tasquinimod significantly reduced the risk of
radiographic cancer progression compared to placebo (rPFS, HR=0.69,
CI 95%: 0.60 - 0.80) in patients with metastatic
castration-resistant prostate cancer (mCRPC) who have not received
chemotherapy, but did not extend overall survival (OS, HR=1.09, CI
95%: 0.94 - 1.28).
· Further development of tasquinimod discontinued and the
collaboration agreement with Ipsen terminated
ISI
· Only commercial activities will be conducted from 2016
Financial summary
| MSEK |
April - June |
|
Jan. - June |
|
Jan. - Dec. |
| |
2015 |
2014 |
|
2015 |
2014 |
|
2014 |
|
| |
|
|
|
|
|
|
|
|
| Net sales |
3.2 |
2.7 |
|
6.1 |
4.9 |
|
10.4 |
|
| |
|
|
|
|
|
|
|
|
| Operating loss |
-70.1 |
-57.9 |
|
-127.5 |
-117.2 |
|
-228.5 |
|
| |
|
|
|
|
|
|
|
|
| Loss for the period |
-71.4 |
-57.7 |
|
-129.3 |
-117.9 |
|
-231.5 |
|
| |
|
|
|
|
|
|
|
|
| Loss per share (SEK) |
-0.79 |
-0.77 |
|
-1.44 |
-1.57 |
|
-3.02 |
|
| |
|
|
|
|
|
|
|
|
| Cash and cash equivalents |
|
|
|
186.6 |
227.7 |
|
328.5 |
|
For further information, please
contact:
Tomas Leanderson, President and
CEO
Tel: +46 (0)46 19 20 95
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
The report is also available at www.activebiotech.com
Active Biotech AB
Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00
Active Biotech AB Interim report
January - June 2015
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
HUG#1944149
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024
